Abstract
Background
Primary open-angle glaucoma (POAG) is the most common subtype of glaucoma. We evaluate the cost-effectiveness of polygenic risk score (PRS) profiling as a screening tool for POAG.
Methods
We used a Markov cohort model to evaluate the cost-effectiveness of implementing PRS screening in the UK and Australia, conducted from the healthcare payer’s perspective. We used published data to calculate prevalence, transition probabilities, utility, cost and other parameters in the model. Our main outcome measure was the incremental cost-effectiveness ratio (ICER) and secondary outcomes were years of blindness avoided and a ‘Blindness ICER’. We did one-way as well as two-way deterministic and probabilistic sensitivity analyses.
Results
The proposed screening programme for POAG in the UK is predicted to result in ICER of £24,783 (95% CI: £13,373–66,960) and would avoid 1 year of blindness at ICER of £10,095 (95% CI: £5513–27,656). In Australia, it is predicted to result in ICER of AU$34,252 (95% CI: AU$21,324–95,497) and would avoid 1 year of blindness at ICER of AU$13,359 (95% CI: AU$8143–37,448). Using the willingness to pay thresholds of $54,808 and £30,000, the proposed screening model is 79.2% likely to be cost-effective in Australia and is 60.2% likely to be cost-effective in the UK, respectively.
Conclusion
We describe and model the cost-efficacy of incorporating a polygenic risk score for POAG screening in Australia and the UK for the first time and results indicated this is a promising cost-effectiveness strategy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 18 print issues and online access
$259.00 per year
only $14.39 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The majority of the data generated or analysed during this study are included in this published article (and its supplementary information files) - e.g., every variable used to generate the model is available in the supplementary tables, with references to the original source. The wide range of output datasets generated during the current study are available from the corresponding author on reasonable request.
References
Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–90.
International Council of Ophthalmology: Resources: Tunnel Vision-The Economic Impact Of Primary Open Angle Glaucoma. [cited 2020 Oct 27]. Available from: http://www.icoph.org/resources/249/Tunnel-Vision-The-Economic-Impact-of-Primary-Open-Angle-Glaucoma.html
Rouland J-F, Berdeaux G, Lafuma A. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review. Drugs Aging. 2005;22:315–21.
Taylor HR, Pezzullo ML, Keeffe JE. The economic impact and cost of visual impairment in Australia. Br J Ophthalmol. 2006;90:272.
Real JP, Lafuente MC, Palma SD, Tártara LI. Direct costs of glaucoma: Relationship between cost and severity of the disease. Chronic Illn. 2020;16:266–74.
Keel S, Xie J, Foreman J, Lee PY, Alwan M, Fahy ET, et al. Prevalence of glaucoma in the Australian National Eye Health Survey. Br J Ophthalmol. 2019;103:191–5.
Gupta P, Zhao D, Guallar E, Ko F, Boland MV, Friedman DS. Prevalence of glaucoma in the United States: the 2005–2008 national health and nutrition examination survey. Invest Ophthalmol Vis Sci. 2016;57:2905–13.
Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization; 1968:163.
Traverso CE, Walt JG, Kelly SP, Hommer AH, Bron AM, Denis P, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol. 2005;89:1245–9.
Lee PP, Walt JG, Doyle JJ, Kotak SV, Evans SJ, Budenz DL, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol. 2006;124:12–9.
Gessesse GW, Damji KF. Advanced glaucoma: management pearls. Middle East Afr J Ophthalmol. 2013;20:131–41.
Burr JM, Mowatt G, Hernández R, Siddiqui MAR, Cook J, Lourenco T, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1–190.
Fingert JH. Primary open-angle glaucoma genes. Eye. 2011;25:587–95. https://doi.org/10.1038/eye.2011.97.
Craig JE, Han X, Qassim A, Hassall M, Cooke Bailey JN, Kinzy TG, et al. Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. Nat Genet. 2020;52:160–6.
Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50:1219–24.
Park N. Analysis of population estimates tool. Office for National Statistics; 2020 [cited 2022 Feb 7]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/analysisofpopulationestimatestool
Commonwealth of Australia, Estimated resident population. 31010 / Jun 2019 / Australian Demographic Statistics / Estimated resident population / Details [Internet]. Australian Bureau of Statistics. 2019 [cited 2020 Oct 16]; Available from: https://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3101.0Jun%202019?OpenDocument
National Institute for Health and Care Excellence. The Way Forward: Glaucoma - options to help meet demand for the current and future care of patients with eye disease [Internet]. [cited 2020 Oct 8]. Available from: https://www.evidence.nhs.uk/document?id=1618377&returnUrl=Search%3Fps%3D40%26q%3Deye%2Bcare&q=eye+care
TreeAge Pro Healthcare [Internet]. [cited 2020 Oct 1]. Available from: https://www.treeage.com/product/treeage-pro-healthcare/
Burr JM, Kilonzo M, Vale L, Ryan M. Developing a preference-based Glaucoma Utility Index using a discrete choice experiment. Optom Vis Sci. 2007;84. [cited 2020 Sep 29]; Available from: https://pubmed.ncbi.nlm.nih.gov/17700343/
Brown MM, Brown GC, Sharma S, Kistler J, Brown H. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001;85:327–31.
McCaffrey N, Kaambwa B, Currow DC, Ratcliffe J. Health-related quality of life measured using the EQ-5D–5L: South Australian population norms. Health Qual Life Outcomes. 2016 ;14:1–12.
Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. York Centre for health economics. University of York; 1999:8.
Dirani M, Crowston JG, Taylor PS, Moore PT, Rogers S, Pezzullo ML, et al. Economic impact of primary open-angle glaucoma in Australia. Clin Experiment Ophthalmol. 2011;39.[cited 2020 Oct 2]; Available from: https://pubmed.ncbi.nlm.nih.gov/21631669/
Australian Institute of Health and Walfare (AIHW). Disease expenditure in Australia [Internet]. [cited 2020 Oct 2]. Available from: https://www.aihw.gov.au/reports/health-welfare-expenditure/disease-expenditure-australia/contents/summary
Australian Institute of Health and Welfare (AIHW). Aged care service list: 30 June 2019 [Internet]. [cited 2020 Oct 2]. Available from: https://www.gen-agedcaredata.gov.au/Resources/Access-data/2019/September/Aged-care-service-list-30-June-2019
McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. Paying the Price: the cost of mental health care in England to 2026. King’s Fund 2008. Website [Internet]. [cited 2020 Oct 15]. Available from: https://www.kingsfund.org.uk/sites/default/files/Paying-the-Price-the-cost-of-mental-health-care-England-2026-McCrone-Dhanasiri-Patel-Knapp-Lawton-Smith-Kings-Fund-May-2008_0.pdf
Australian Institute of Health and Welfare (AIHW). Trends in hospitalised injury due to falls in older people 2007–08 to 2016–17 [Internet]. [cited 2020 Oct 2]. Available from: https://www.aihw.gov.au/reports/injury/trends-in-hospitalised-injury-due-to-falls/contents/table-of-contents
Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385:1295–304.
Australian Bureau of Statistics. Deaths, Year of occurrence, Age at death, Age-specific death rates, Sex, States, Territories and Australia [Internet]. [cited 2020 Oct 15]. Available from: http://stat.data.abs.gov.au/Index.aspx?DataSetCode=DEATHS_AGESPECIFIC_OCCURENCEYEAR
Morgan E. Mortality rates (qx), principal projection, England and Wales [Internet]. Office for National Statistics; 2019 [cited 2020 Oct 16]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/mortalityratesqxprincipalprojectionenglandandwales
Parliament of Australia. Report – Availability of new, innovative and specialist cancer drugs in Australia [Internet]. [cited 2020 Sep 30]. Available from: https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/Cancer_Drugs/Report
McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold. PharmacoEconomics. 2008;26:733–44. https://doi.org/10.2165/00019053-200826090-00004.
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–79.
Burr J, Hernández R, Ramsay C, Prior M, Campbell S, Azuara-Blanco A, et al. Is it worthwhile to conduct a randomized controlled trial of glaucoma screening in the United Kingdom? J Health Serv Res Policy. 2014;19:42–51.
Office of the Commissioner. FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions [Internet]. 2017 [cited 2020 Sep 28]. Available from: https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-first-direct-consumer-tests-provide-genetic-risk-information-certain-conditions
Callender T, Emberton M, Morris S, Eeles R, Kote-Jarai Z, Pharoah PDP, et al. Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study. PLOS Med. 2019;16:e1002998 https://doi.org/10.1371/journal.pmed.1002998.
Naber SK, Kundu S, Kuntz KM, Dotson WD, Williams MS, Zauber AG, et al. Cost-effectiveness of risk-stratified colorectal cancer screening based on polygenic risk: current status and future potential. JNCI Cancer Spectr. 2020;4:kz086.
Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J, et al. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2017;109. Available from: https://doi.org/10.1093/jnci/djw302
Beckers HJM, Schouten JSAG, Webers CAB, van der Valk R, Hendrikse F. Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. Graefes Arch Clin Exp Ophthalmol. 2008;246:1485–90.
Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Investigative Opthalmology Vis Sci. 2006;47:4254 https://doi.org/10.1167/iovs.06-0299.
Manchanda R, Patel S, Gordeev VS, Antoniou AC, Smith S, Hopper JL, et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. JNCI: J Natl Cancer Inst. 2018;110:714–25. https://doi.org/10.1093/jnci/djx265.
Sonic Genetics. Solid tumour panel (Find It) [Internet]. [cited 2022 July 17]. Available from: https://www.sonicgenetics.com.au/our-tests/all-tests/solid-tumour-panel-find-it/
Department of Health, Australian Government. Medicare Benefits Schedule -Item 10910 [Internet]. [cited 2020 Nov 15]. Available from: http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&qt=ItemID&q=10910
Violato M, Dakin H, Chakravarthy U, Reeves BC, Peto T, Hogg RE, et al. Cost-effectiveness of community versus hospital eye service follow-up for patients with quiescent treated age-related macular degeneration alongside the ECHoES randomised trial. BMJ Open. 2016;6:e011121.
Rahman MQ, Beard SM, Discombe R, Sharma R, Montgomery DM. Direct healthcare costs of glaucoma treatment. Br J Ophthalmol. 2013;97. [cited 2020 Oct 15]; Available from: https://pubmed.ncbi.nlm.nih.gov/23590855/
Care Markets and LaingBuisson. Annual Survey of UK Local Authority Usual Costs 2017/2018 [Internet]. [cited 2020 Nov 5]. Available from: https://www.laingbuisson.com/wp-content/uploads/sites/3/2017/07/CareMarkets_UsualCosts_20172018.pdf
Australian Institute of Health and Welfare (AIHW). Admitted patient care 2017-18 [Internet]. [cited 2020 Nov 5]. Available from: https://www.aihw.gov.au/getmedia/df0abd15-5dd8-4a56-94fa-c9ab68690e18/aihw-hse-225.pdf.aspx?inline=true
McGinley P, Ansari E, Sandhu H, Dixon T. The cost burden of falls in people with glaucoma in National Health Service Hospital Trusts in the UK. [cited 2020 Nov 5]. Available from: https://doi.org/10.1080/13696998.2019.1646262
Varma R, Lee PP, Goldberg I, Kotak S. An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol. 2011;152:515.
Acknowledgements
DAM, SM, JEC, LS and AWH are supported by the Australian National Health and Medical Research Council (NHMRC) Fellowships. XH is supported by the University of Queensland Research Training Scholarship and QIMR Berghofer Medical Research Institute PhD Top Up Scholarship. We are grateful for funding from a NHMRC Programme grant (1150144), Partnership grant (1132454) and a Centre for Research Excellence grant (1116360).
Funding
We had funding from a NHMRC Programme grant (1150144), Partnership grant (1132454) and a Centre for Research Excellence grant (1116360).
Author information
Authors and Affiliations
Contributions
The contribution each author made to the manuscript is listed as following: (1) Conceptualisation: AWH, LS, JD, QL (2) Data curation: JD, QL (3) Formal Analysis: JD, LS (4) Funding acquisition: AWH, LS, DAM, SM, JEC (5) Investigation: QL, JD (6) Methodology: AWH, LS, JD, QL (7) Project administration: AWH (8) Resources: N/A. (9) Software: AWH (10) Supervision: LS, AWH (11) Validation: LS, JD (12) Visualisation: JD (13) Writing- original draft: 80% by QL, 20% by JD (14) Writing- review and editing: AWH, LS, XH, DAM, SM, JEC.
Corresponding authors
Ethics declarations
Competing interests
SM, JEC, and AWH are listed as co-inventors on a patent application (WO2019241844A1) for the use of genetic risk scores to determine risk and guide treatment for glaucoma.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Liu, Q., Davis, J., Han, X. et al. Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia. Eye 37, 2335–2343 (2023). https://doi.org/10.1038/s41433-022-02346-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41433-022-02346-2